Good science is not enough. Someone has to build the line.

Most diagnostics ramps fail not because the science was wrong, but because nobody owns the transition from the lab to the production floor. I have been in enough of these situations to know the pattern. The assay works beautifully in development. Then it hits manufacturing conditions, and something changes. Different dispensing technology, different process parameters, different behaviour when you are running volume instead of samples. The re-validation starts. Six months become twelve. The launch window closes quietly, and nobody writes a press release about it.

This is the problem I have spent most of my career trying to solve, and it is why the work we did with VTT's PrintoCent facility is worth sharing. Kari Rönkä, who was Research Team Leader at VTT at the time and is now Vice President of Sensing Solutions there, explains in this video what it actually takes to develop roll-to-roll compatible dispensing for bioactive materials. The core requirement is depositing very small and accurate amounts of material consistently under production conditions. Nanoliter volumes. Viscous, temperature-sensitive reagents that behave differently at production speed than they do on a bench. An inconsistency at that scale does not announce itself. It shows up later in QC or in a clinical result, which is not where you want to find it.

What we built together addresses exactly that. A dispensing system for bioactive materials in a roll-to-roll context, with verification built in so developers know what is actually being deposited. Kari recommends the pump technology, the service flexibility, and the verification processes. I appreciate that. But the reason I am sharing this is not the recommendation. It is because most of the conversation in this industry is still happening on the science side, and the production side is where things actually succeed or fail. The companies that will lead the next decade of microfluidics are the ones that understand both.